Your browser doesn't support javascript.
loading
A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization.
Harwardt, Julia; Bogen, Jan P; Carrara, Stefania C; Ulitzka, Michael; Grzeschik, Julius; Hock, Björn; Kolmar, Harald.
Afiliação
  • Harwardt J; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
  • Bogen JP; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
  • Carrara SC; Ferring Darmstadt Laboratory, Biologics Technology and Development, Darmstadt, Germany.
  • Ulitzka M; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
  • Grzeschik J; Ferring Darmstadt Laboratory, Biologics Technology and Development, Darmstadt, Germany.
  • Hock B; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
  • Kolmar H; Ferring Darmstadt Laboratory, Biologics Technology and Development, Darmstadt, Germany.
Front Immunol ; 13: 888838, 2022.
Article em En | MEDLINE | ID: mdl-35479092
ABSTRACT
Various formats of bispecific antibodies exist, among them Two-in-One antibodies in which each Fab arm can bind to two different antigens. Their IgG-like architecture accounts for low immunogenicity and also circumvents laborious engineering and purification steps to facilitate correct chain pairing. Here we report for the first time the identification of a Two-in-One antibody by yeast surface display (YSD) screening of chicken-derived immune libraries. The resulting antibody simultaneously targets the epidermal growth factor receptor (EGFR) and programmed death-ligand 1 (PD-L1) at the same Fv fragment with two non-overlapping paratopes. The dual action Fab is capable of inhibiting EGFR signaling by binding to dimerization domain II as well as blocking the PD-1/PD-L1 interaction. Furthermore, the Two-in-One antibody demonstrates specific cellular binding properties on EGFR/PD-L1 double positive tumor cells. The presented strategy relies solely on screening of combinational immune-libraries and obviates the need for any additional CDR engineering as described in previous reports. Therefore, this study paves the way for further development of therapeutic antibodies derived from avian immunization with novel and tailor-made binding properties.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Antígeno B7-H1 Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Antígeno B7-H1 Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article